Deutsche Bank AG Purchases 64,997 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

Deutsche Bank AG raised its holdings in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 57.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 177,383 shares of the company's stock after buying an additional 64,997 shares during the quarter. Deutsche Bank AG owned 0.11% of Revolution Medicines worth $7,759,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Barclays PLC lifted its stake in Revolution Medicines by 187.1% in the third quarter. Barclays PLC now owns 294,664 shares of the company's stock valued at $13,362,000 after buying an additional 192,021 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in shares of Revolution Medicines by 92.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 61,980 shares of the company's stock valued at $2,711,000 after acquiring an additional 29,853 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Revolution Medicines by 9.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,931,114 shares of the company's stock valued at $84,467,000 after acquiring an additional 167,997 shares in the last quarter. Sandy Cove Advisors LLC bought a new stake in shares of Revolution Medicines during the fourth quarter valued at approximately $1,837,000. Finally, Russell Investments Group Ltd. increased its holdings in shares of Revolution Medicines by 11.4% during the fourth quarter. Russell Investments Group Ltd. now owns 4,243 shares of the company's stock valued at $186,000 after acquiring an additional 434 shares in the last quarter. 94.34% of the stock is owned by institutional investors and hedge funds.

Revolution Medicines Stock Performance

NASDAQ:RVMD traded up $0.97 during trading on Friday, reaching $39.77. The company's stock had a trading volume of 1,398,581 shares, compared to its average volume of 1,491,420. The firm has a market cap of $7.41 billion, a price-to-earnings ratio of -11.08 and a beta of 1.11. The firm has a 50 day moving average of $37.55 and a 200-day moving average of $42.66. Revolution Medicines, Inc. has a 12 month low of $29.17 and a 12 month high of $62.40.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.01). During the same quarter in the previous year, the company posted ($0.70) earnings per share. Equities research analysts forecast that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on RVMD. HC Wainwright restated a "buy" rating and set a $72.00 price objective (down previously from $73.00) on shares of Revolution Medicines in a report on Wednesday, May 14th. Stifel Nicolaus decreased their price objective on Revolution Medicines from $78.00 to $64.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Needham & Company LLC restated a "buy" rating and set a $57.00 price objective on shares of Revolution Medicines in a report on Thursday, May 8th. Wedbush reiterated an "outperform" rating and set a $67.00 price target on shares of Revolution Medicines in a report on Thursday, May 8th. Finally, Oppenheimer upped their price target on Revolution Medicines from $70.00 to $75.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Revolution Medicines presently has a consensus rating of "Buy" and an average target price of $67.08.

Insider Buying and Selling at Revolution Medicines

In other Revolution Medicines news, COO Margaret A. Horn sold 3,058 shares of the company's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $39.04, for a total value of $119,384.32. Following the completion of the transaction, the chief operating officer now owns 153,533 shares in the company, valued at $5,993,928.32. This represents a 1.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Jack Anders sold 1,864 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $39.04, for a total value of $72,770.56. Following the transaction, the chief financial officer now owns 115,006 shares of the company's stock, valued at $4,489,834.24. The trade was a 1.59% decrease in their position. The disclosure for this sale can be found here. Insiders sold 16,660 shares of company stock worth $650,406 in the last quarter. 8.20% of the stock is currently owned by company insiders.

Revolution Medicines Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.